When Baby Screening for Type 1 Diabetes May Show False Positives: What Parents Should Know

If you've had a baby tested for Type 1 diabetes autoantibodies and received a positive result, you may feel alarmed. But new findings from a French research cohort suggest the picture is more complicated than a simple yes or no answer—especially if your baby is under 1 year old.

The TRAKR study followed 148 children born to parents with Type 1 diabetes, testing their blood at birth and several points over the first three years of life. At 8 months, about 20% of babies tested positive for islet autoantibodies—the immune markers associated with Type 1 diabetes. However, the researchers found that most of these positive results likely came from a surprising source: antibodies passed from mother to baby during pregnancy.

During pregnancy, mothers naturally transfer protective antibodies to their babies through the placenta. This is beneficial for newborns, giving them temporary immunity to infections their mothers have encountered. But for babies born to mothers with Type 1 diabetes, this transfer can include islet autoantibodies—the very antibodies linked to autoimmune diabetes.

In the TRAKR study, 85.7% of antibody-positive infants had antibodies that matched their mother's specific autoantibody profile. The most common match was GADA (an antibody to the enzyme GAD). All 9 babies who tested positive for GADA at 8 months had mothers who were also GADA-positive. This wasn't coincidence—it was maternal transfer.

What makes this important: these passively transferred antibodies typically disappear on their own. In the study, 6 out of 7 GADA-positive babies cleared the antibody by 18 months, and all 5 babies who initially tested positive for IAA (another autoantibody type) had cleared it by 18 months as well.

The current uncertainty about when to begin screening stems from wanting to catch autoimmunity early while avoiding unnecessary worry. This study suggests that screening during the first year of life may identify more maternal antibodies than actual childhood autoimmunity, potentially leading families down a path of unnecessary follow-up testing and anxiety.

The researchers propose that starting screening at age 2 instead of during infancy could reduce these false alarms while still detecting children who are developing their own autoimmune response. By age 2, maternal antibodies have naturally faded, making it easier to distinguish a baby's own emerging autoimmunity from antibodies simply inherited from mom.

Only 1 child in the entire TRAKR cohort progressed to clinical Type 1 diabetes during the study period—a child who developed autoantibodies at 18 months that were different from their mother's, suggesting genuine autoimmunity rather than passive transfer. This child was diagnosed at Stage 3 (the earliest symptomatic stage) at 30 months, without progressing to ketoacidosis.

If you're a parent with Type 1 diabetes and considering screening for your child, or if your baby has tested positive for autoantibodies, these findings offer important context for a conversation with your diabetes care team or pediatrician. Ask whether screening timing makes sense for your family, whether a positive result at 8 months reflects maternal transfer, and what follow-up (if any) would be appropriate.

This research doesn't change the importance of monitoring high-risk children—those with a family history of Type 1 diabetes remain at higher risk. Rather, it refines our understanding of what early positive tests actually mean and suggests that age matters when interpreting results. Clearer screening timelines could reduce unnecessary worry while maintaining vigilance for children who genuinely need monitoring.

Source: Diabetes & metabolism. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.